Imagine you are diagnosed with a rare and potentially fatal disease that requires treatments costing hundreds of thousands that you do not have. Should tax payers - through publically funded health insurance - be obliged to carry that cost? “It depends”, you may think, on factors such as how old you are and how effective the treatment is. But how should such decisions be made, and who should be burdened with making such life and death decisions?
Med-Tech Innovation in Germany as Reference Case for Europe